ImpaQ Ecosystem•Clarivate, Scopus & CORE Data
Clarivate WoS 2024 / 2025 Data
IMPAQ
WoS SCIE Q2Scopus Q1SCImago #1,116Gold OA

Neoplasia

Acronym:neo
•
Abbreviation (ISO):NEOPLASIA
•
Identifier (ISSN):1522-8002(Print)/1476-5586(Online)
•
Publisher:Neoplasia Press
Clarivate IF (2026)
4.8↓ -2.9
Journal Impact Factor
IF Trend↓
WoS Quartile
Q2
WoS SCIEJCR Quartile
Clarivate WoS JCR
WoS Categories↓
JCR Release Date: 2026-06-17

Impact Factor Trend (2020–2026)

Clarivate IF trend for Neoplasia

WoS Q2
358105.720205.7120216.2220224.820237.720254.82026
Annual Impact Factor Metric
Current (2026):4.8
Scopus SJR & RankScopus Q1
2.284
#1,116

SCImago Journal Rank citation prestige weighting

Scopus Year: 2025
H-Index (2025)
151

151 papers with at least that number of citations each

WoS: SCIE / JCRQ2
Self-Citation Rate1.6%
Safe Level (< 15%)Warning Level (> 20%)
Self-citation below 15% indicates strong scholarly independence.
Volume & Open AccessGold OA
111articles/year
100% Gold OA•93.62% Original Research

Aims & Scope

Neoplasia publishes the results of novel investigations in all areas of oncology research. The title Neoplasia was chosen to convey the journal’s breadth, which encompasses the traditional disciplines of cancer research as well as emerging fields and interdisciplinary investigations. Neoplasia is interested in studies describing new molecular and genetic findings relating to the neoplastic phenotype and in laboratory and clinical studies demonstrating creative applications of advances in the basic sciences to risk assessment, prognostic indications, detection, diagnosis, and treatment. In addition to regular Research Reports, Neoplasia also publishes Reviews and Meeting Reports. Neoplasia is committed to ensuring a thorough, fair, and rapid review and publication schedule to further its mission of serving both the scientific and clinical communities by disseminating important data and ideas in cancer research.

Topics Covered (Recognized by AI)
Biology97.8%Genetics95.7%Medicine94.9%Chemistry88.7%Internal medicine87.1%Biochemistry86.6%Cancer research81.5%Cancer67.7%Gene62.2%Cell biology44.6%Pathology39.4%Immunology34.7%Apoptosis29.9%Cell culture24.7%Molecular biology24%Signal transduction22.5%Receptor20.9%Cell20.2%
Primary Research Areas

WoS Categories & Quartiles

Detailed JCR / JCI category rankings and quartile breakdown from Clarivate

Clarivate JCR & JCI
JCRSCIE2026

ONCOLOGY

Q2
Rank92/333
IndexSCIE
JCISCIE2026

ONCOLOGY

Q1
Rank47/333
IndexSCIE

Annual Historical Statistics & Publications

Track annual publication volume, total citations, and Impact Factor evolution

12 year
2026Latest
IF4.8
Articles / Year95
Total Citations76
2025
IF7.7
Articles / Year137
Total Citations549
2024
IF—
Articles / Year151
Total Citations1,262
2023
IF4.8
Articles / Year83
Total Citations1,398
2022
IF6.218
Articles / Year92
Total Citations4,825

SCImago & Scopus Journal Intelligence

Global SCImago ranking, SJR prestige index, Scopus coverage, and societal policy impact

Rank #1,116Scopus Q1SCImago Profile
Scopus Coverage:1999-2026
Scopus Broad Areas:Biochemistry, Genetics and Molecular Biology
Scopus Citation Rank (SJR)Q1
2.284

Weighted prestige citation metric per document indexed in the Scopus database.

Quartile: Scopus Q1
Citations / Doc (2 years)
5.17

Average citations received per document published in the 2-year window.

2-Year Citation Window
Estimated Publication Fee (APC)
$3,726 USD

Estimated Article Processing Charge for Open Access publication.

Estimated cost / article

Scopus 3-Year Publication & Citation Window

3-Year Citations2,158
3-Year Documents282
Citable Documents280

Aggregated from Scopus database across the 3-year SJR evaluation window.

Societal Impact & Inclusivity (SCImago)

Policy Citations (Overton)2

Citations in government and international policy documents

Female Author Rate44.0%

Percentage of female authors published in the journal

Real-world societal policy reach and author gender diversity tracked by SCImago.

Scopus Subject Categories

Cancer ResearchQ1
Academic Metric Intelligence

Journal Metrics & Citation Visualizations

Total Cites vs Self-Cites

Evaluation of scholarly independence and citation reach

Total citations steady growth
Self-citation: 1.6%

Citations per Document

Citation metric windows across 2, 3, and 4 years

Cites / Doc (4 years)Cites / Doc (3 years)Cites / Doc (2 years)

Chinese Academy of Sciences (CAS) Classification

Major / minor zone classification and CAS Early Warning List history

Major Category (Broad Field):
2区 (Zone 2)Medicine
Minor Category (Specific Field):
2区ONCOLOGY
CAS Early Warning List History:
Updated annually: 2020 – 2024
2020
Not warned
2021
Not warned
2022
Not warned
2023
Not warned
2024
Not warned

Academic Intelligence Overview & Context

ImpaQ Analysis

Neoplasia (acronym: neo, abbr: NEOPLASIA, ISSN: 1522-8002) is a peer-reviewed international scholarly journal in the field of Medicine, published by Neoplasia Press in United States since 1999. The periodical holds a Journal Impact Factor (JIF) of 4.80, ranking in quartile Q2 of Web of Science (SCIE), a Scopus SJR indicator of 2.284 (Q1), an H-index of 151.

The journal enforces rigorous peer evaluation with a publication frequency of Monthly, an annual output of approximately 111 scientific articles. In terms of accessibility and author fees, it operates under the Gold OA model with an estimated APC of $3,726 USD. It serves as a benchmark publication platform for academics, researchers, and doctoral candidates seeking global research visibility.

Publishing & Editorial Information

Detailed publisher, peer-review turnaround, and publication cycle specifications

Open Access Model
Gold OA
Publisher
Neoplasia Press
Publication Language
English
Frequency
Monthly
Founding Year
1999
Indexing & Databases
SCIEScopusDOAJPubMed
Editorial Address
NEOPLASIA PRESS, 1150 W MEDICAL CENTER DR, MSRB III, RM 9303, ANN ARBOR, USA, MI, 48109-0648

Similar Journals in Discipline

Journals in the same research field with comparable impact metrics

Record UUID: ae4d6573-9213-4eb0-9a25-8a65e544ccb6
Database Updated: 2026-10-27